Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 6, 2008, Pages

  Stein, Miguel L ^a   Villanueva, Joyce M ^a   Buckmeier, Bridget K ^a   Yamada, Yoshiyuki ^a   Filipovich, Alexandra H ^a   Assa'ad, Amal H ^a   Rothenberg, Marc E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anti IL 5; cytokines; eosinophilia; esophagitis; hypereosinophilic; IL 5; inflammation; mepolizumab

Indexed keywords

BECLOMETASONE; BUDESONIDE; CHEMOKINE RECEPTOR CCR3; CYCLOPHOSPHAMIDE; EOTAXIN; HYDROCORTISONE; HYDROXYUREA; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 5 RECEPTOR; INTERLEUKIN 5 RECEPTOR ALPHA; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; OMALIZUMAB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN A; PROTEIN G; PROTON PUMP INHIBITOR; STEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; BURNING SENSATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPNEA; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; EX VIVO STUDY; FEMALE; FILTRATION; FLUSHING; FUSION GENE; HEADACHE; HUMAN; HYPEREOSINOPHILIA; IMMUNOREACTIVITY; LYMPHOCYTOPOIESIS; MALE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 44649103777     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.02.033     Document Type: Article

References (35)

1. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
2. Rosenberg H.F., Phipps S., and Foster P.S. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 119 (2007) 1303-1310
3. Owen W.F., Rothenberg M.E., Petersen J., Weller P.F., Silberstein D., Sheffer A.L., et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 170 (1989) 343-348
4. Roufosse F., Schandene L., Sibille C., Willard-Gallo K., Kennes B., Efira A., et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 109 (2000) 540-548
5. Samoszuk M., and Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75 (1990) 13-16
6. Simon H.U., Plotz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
7. Rothenberg M.E. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 113 (2004) 11-28
8. Straumann A., Bauer M., Fischer B., Blaser K., and Simon H.U. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108 (2001) 954-961
9. Mishra A., Hogan S.P., Brandt E.B., and Rothenberg M.E. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol 168 (2002) 2464-2469
10. Rennick D.M., Thompson-Snipes L., Coffman R.L., Seymour B.W., Jackson J.D., and Hudak S. In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice. Blood 76 (1990) 312-316
11. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., and Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183 (1996) 195-201
12. Mishra A., Hogan S.P., Brandt E.B., and Rothenberg M.E. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest 107 (2001) 83-90
13. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
14. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., and Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003) 199-204
15. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167 (2003) 1655-1659
16. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
17. Plotz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
18. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
19. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
20. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 (2006) 1312-1319
21. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228
22. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H.U., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
23. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
24. Zimmermann N., and Rothenberg M.E. Receptor internalization is required for eotaxin-induced responses in human eosinophils. J Allergy Clin Immunol 111 (2003) 97-105
25. Solbach W. Tumor-promoting phorbol esters selectively abrogate the expression of the T4 differentiation antigen expressed on normal and malignant (Sezary) T helper lymphocytes. J Exp Med 156 (1982) 1250-1255
26. Petersen C.M., Christensen E.I., Andresen B.S., and Moller B.K. Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cells. Exp Cell Res 201 (1992) 160-173
27. Kogawa K., Lee S.M., Villanueva J., Marmer D., Sumegi J., and Filipovich A.H. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood 99 (2002) 61-66
28. Sabroe I., Hartnell A., Jopling L.A., Bel S., Ponath P.D., Pease J.E., et al. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol 162 (1999) 2946-2955
29. Finkelman F.D., Madden K.B., Morris S.C., Holmes J.M., Boiani N., Katona I.M., et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151 (1993) 1235-1244
30. Minamitake Y., Kodama S., Katayama T., Adachi H., Tanaka S., and Tsujimoto M. Structure of recombinant human interleukin 5 produced by Chinese hamster ovary cells. J Biochem (Tokyo) 107 (1990) 292-297
31. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 (1992) 3101-3109
32. Tavernier J., Van der Heyden J., Verhee A., Brusselle G., Van Ostade X., Vandekerckhove J., et al. Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. Blood 95 (2000) 1600-1607
33. Swartz J.M., Dyer K.D., Cheever A.W., Ramalingam T., Pesnicak L., Domachowske J.B., et al. Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood 108 (2006) 2420-2427
34. Kim Y.J., Prussin C., Martin B., Law M.A., Haverty T.P., Nutman T.B., et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 114 (2004) 1449-1455
35. Zia-Amirhosseini P., Minthorn E., Benincosa L.J., Hart T.K., Hottenstein C.S., Tobia L.A., et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291 (1999) 1060-1067